Non–Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of 18F-FDG Uptake at PET—Association with Treatment Response and Prognosis

Gary J R Cook*, Mary E. O'Brien, Muhammad Siddique, Sugama Chicklore, Hoi Y. Loi, Bhupinder Sharma, Ravi Punwani, Paul Bassett, Vicky Goh, Sue Chua, Sugama Chicklore

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

146 Citations (Scopus)

Abstract

Purpose

To determine if first-order and high-order textural features on fluorine 18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET) images of non–small cell lung cancer (NSCLC) (a) at baseline, (b) at 6 weeks, or (c) the percentage change between baseline and 6 weeks can predict response or survival in patients treated with erlotinib.

Materials and Methods

Institutional review board approval was obtained for post hoc analysis of data from a prospective single-center study for which informed consent was obtained. The study included 47 patients with NSCLC who underwent 18F-FDG PET/computed tomography (CT) at baseline (n = 47) and 6 weeks (n = 40) after commencing treatment with erlotinib. First-order and high-order primary tumor texture features reflecting image heterogeneity, standardized uptake values, metabolic tumor volume, and total lesion glycolysis were measured for all 18F-FDG PET studies. Response to erlotinib was assessed by using the Response Evaluation Criteria in Solid Tumors (RECIST) on CT images obtained at 12 weeks (n = 32). Associations between PET parameters, overall survival (OS), and RECIST-based treatment response were tested by Cox and logistic regression analyses, respectively.

Results

Median OS was 14.1 months. According to CT RECIST at 12 weeks, there were 21 nonresponders and 11 responders. Response to erlotinib was associated with reduced heterogeneity (first-order standard deviation, P = .01; entropy, P = .001; uniformity, P = .001). At multivariable analysis, high-order contrast at 6 weeks (P = .002) and percentage change in first-order entropy (P = .03) were independently associated with survival. Percentage change in first-order entropy was also independently associated with treatment response (P = .01).

Conclusion

Response to erlotinib is associated with reduced heterogeneity at 18F-FDG PET. Changes in first-order entropy are independently associated with OS and treatment response.

Original languageEnglish
Pages (from-to)883-893
Number of pages11
JournalRadiology
Volume276
Issue number3
Early online date17 Aug 2015
DOIs
Publication statusPublished - 1 Sept 2015

Fingerprint

Dive into the research topics of 'Non–Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of 18F-FDG Uptake at PET—Association with Treatment Response and Prognosis'. Together they form a unique fingerprint.

Cite this